600178 Disclosed are azaadamantane derivatives of formula (I) wherein L1 is –O- or –NRa-; A is – Ar2-L2-Ar3; wherein Ar2 is a 5 or 6-membered monocyclic heteroaryl and Ar3 is heteroaryl and the substituents are further defined within the specification. Examples of such compounds include (4s)-4-[6-(1H-indol-5-yl)pyridazin-3-yloxy]-1-azatricyclo[3.3.1.13,7]decane, (4s)-4- [5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-yloxy]-1-azatricyclo[3.3.1.13,7]decane and (4s)-4-[5-(1H-indol-5-yl)-thiazol-2-yloxy]-1-azatricyclo[3.3.1.13,7]decane. Also disclosed are N-borane and N-oxide complexes of the claimed compounds, processes for the preparation of the compounds of the invention, compositions comprising said compounds and uses thereof. The compounds are useful as nicotinic acetylcholine receptor ligands and are therefore useful in the treatment of conditions or disorders such as attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease (AD), mild cognitive impairment, schizophrenia and age-associated memory impairment.
Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands